Profarma Distribuidora de Produtos Farmacêuticos Balance Sheet Health
Financial Health criteria checks 5/6
Profarma Distribuidora de Produtos Farmacêuticos has a total shareholder equity of R$1.6B and total debt of R$743.3M, which brings its debt-to-equity ratio to 45.9%. Its total assets and total liabilities are R$5.1B and R$3.5B respectively. Profarma Distribuidora de Produtos Farmacêuticos's EBIT is R$303.3M making its interest coverage ratio 2.2. It has cash and short-term investments of R$231.3M.
Key information
45.9%
Debt to equity ratio
R$743.29m
Debt
| Interest coverage ratio | 2.2x |
| Cash | R$231.28m |
| Equity | R$1.62b |
| Total liabilities | R$3.49b |
| Total assets | R$5.12b |
Recent financial health updates
Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Has A Somewhat Strained Balance Sheet
Dec 19
These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Feb 21These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Jun 08These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Sep 26Here's Why Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Weighed Down By Its Debt Load
May 28Is Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Using Too Much Debt?
Jan 05Recent updates
Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Has A Somewhat Strained Balance Sheet
Dec 19Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)
Nov 02Shareholders Will Be Pleased With The Quality of Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Earnings
Aug 14Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) 28% Price Boost Is Out Of Tune With Earnings
Mar 01These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Feb 21Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)
Nov 04Investors Will Want Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Growth In ROCE To Persist
Aug 03These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Jun 08These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Sep 26Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Shares Fly 26% But Investors Aren't Buying For Growth
Jan 01Here's Why Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Weighed Down By Its Debt Load
May 28Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Might Have The Makings Of A Multi-Bagger
May 07How Much Of Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Do Institutions Own?
Mar 10Are Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 02
Is Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Using Too Much Debt?
Jan 05What Type Of Shareholders Make Up Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) Share Registry?
Dec 10Financial Position Analysis
Short Term Liabilities: PFRM3's short term assets (R$3.6B) exceed its short term liabilities (R$2.6B).
Long Term Liabilities: PFRM3's short term assets (R$3.6B) exceed its long term liabilities (R$924.2M).
Debt to Equity History and Analysis
Debt Level: PFRM3's net debt to equity ratio (31.6%) is considered satisfactory.
Reducing Debt: PFRM3's debt to equity ratio has reduced from 72.1% to 45.9% over the past 5 years.
Debt Coverage: PFRM3's debt is well covered by operating cash flow (63.1%).
Interest Coverage: PFRM3's interest payments on its debt are not well covered by EBIT (2.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:20 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Profarma Distribuidora de Produtos Farmacêuticos S.A. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Diego Moreno | BofA Global Research |
| Guilherme Assis | Brasil Plural |
| Joao dos Santos | BTG Pactual |